Clinical benefit of first-line cemiplimab in patients with locally advanced NSCLC: subgroup analysis from EMPOWER-lung 1

dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.contributor.authorBondarenko, I.
dc.contributor.authorSezer, A.
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorGümüş, M.
dc.contributor.authorÖzgüroğlu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorurk, H. M.
dc.contributor.authorCicin, I.
dc.date.accessioned2021-11-15T08:48:00Z
dc.date.available2021-11-15T08:48:00Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstract[No Abstract Available]en_US
dc.identifier.citationBondarenko, I., Sezer, A., Kilickap, S., Gümüş, M., Özgüroğlu, M., Gogishvili, M., ... & Rietschel, P. (2021). FP04. 03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1. Journal of Thoracic Oncology, 16(10), S951.en_US
dc.identifier.endpageS951en_US
dc.identifier.issn1556-0864en_US
dc.identifier.issn1556-1380en_US
dc.identifier.issue10en_US
dc.identifier.startpageS951en_US
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2021.08.217
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2235
dc.identifier.volume16en_US
dc.identifier.wosWOS:000709606500217en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherELSEVIER SCIENCE INCen_US
dc.relation.ispartofJOURNAL OF THORACIC ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleClinical benefit of first-line cemiplimab in patients with locally advanced NSCLC: subgroup analysis from EMPOWER-lung 1en_US
dc.typeOtheren_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: